Skip to Content
Merck

A265

ARL 67156 trisodium salt hydrate

≥98% (HPLC), solid, ecto-ATPase inhibitor

Synonym(s):

6-N,N-Diethyl-β-γ-dibromomethylene-D-adenosine-5′-triphosphate trisodium salt hydrate, FPL 67156

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C15H21Br2N5Na3O12P3 · xH2O
CAS Number:
160928-38-1
Molecular Weight:
785.05 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
24278252
NACRES:
NA.77
MDL number:
MFCD12910436
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

ARL 67156 trisodium salt hydrate, ≥98% (HPLC), solid

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

white to off-white

solubility

H2O: >20 mg/mL, DMSO: insoluble

storage temp.

−20°C

SMILES string

O.[Na+].[Na+].[Na+].CCN(CC)c1ncnc2n(cnc12)[C@@H]3O[C@H](COP(O)(=O)OP([O-])(=O)C(Br)(Br)P([O-])([O-])=O)[C@@H](O)[C@H]3O

InChI

1S/C15H24Br2N5O12P3.3Na.H2O/c1-3-21(4-2)12-9-13(19-6-18-12)22(7-20-9)14-11(24)10(23)8(33-14)5-32-37(30,31)34-36(28,29)15(16,17)35(25,26)27;;;;/h6-8,10-11,14,23-24H,3-5H2,1-2H3,(H,28,29)(H,30,31)(H2,25,26,27);;;;1H2/q;3*+1;/p-3/t8-,10-,11-,14-;;;;/m1..../s1

InChI key

UWMONIJVKGTUGE-OPKBHZIBSA-K

Gene Information

human ... ENTPD2(954)

Related Categories

General description

ARL 67156, a nucleotide/ATP analog is a competitive inhibitor of CD39. This ecto-ATPase inhibitor is presumed to be metabolically stable in biological studies due to its β, γ-dibromomethylene bridge.
ARL-67156 preferentially inhibits the degradation of ADP compared to the degradation of ATP in the murine colon. It is commonly employed to inhibit ATP hydrolysis in tissue preparations.

Application

ARL 67156 trisodium salt hydrate has been used:
  • to prevent ATP degradation during cerebrospinal fluid extraction
  • as an ATPase inhibitor in ATP quantification assay for preventing ATP degradation in cytoplasm and mitochondrion
  • as an ecto-ATPase inhibitor to treat cancer cells for ATP release assay

Biochem/physiol Actions

ecto-ATPase inhibitor; prevents metabolism of P2 purinoceptor agonists.

Storage Class

11 - Combustible Solids

wgk

WGK 3

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

Substances Subject to be Indicated Names

ishl_indicated

Substances Subject to be Notified Names

ishl_notified

A265-25MG:4548174007891 + A265-BULK: + A265-5MG:4548174007907 + A265-IP: + A265-VAR:

jan

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000212156
0000212151
0000212156
0000212151
0000210941

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

B E Crack et al.
British journal of pharmacology, 114(2), 475-481 (1995-01-01)
1. FPL 67156 (6-N,N-diethyl-beta, gamma-dibromomethylene-D-ATP), is a newly synthesized analogue of ATP. 2. In a rabbit isolated tracheal epithelium preparation, measuring P2U-purinoceptor-dependent chloride secretion, FPL 67156 was discovered to potentiate the responses to UTP but not those to ATP-gamma-S. UTP
S A Lévesque et al.
British journal of pharmacology, 152(1), 141-150 (2007-07-03)
ARL 67156, 6-N,N-Diethyl-D-beta-gamma-dibromomethylene adenosine triphosphate, originally named FPL 67156, is the only commercially available inhibitor of ecto-ATPases. Since the first report on this molecule, various ectonucleotidases responsible for the hydrolysis of ATP at the cell surface have been cloned and
A commonly used ecto-ATPase inhibitor, ARL-67156, blocks degradation of ADP more than the degradation of ATP in murine colon
Durnin L, et al.
Neurogastroenterology and Motility (2016)
Laura Schäkel et al.
Frontiers in pharmacology, 11, 1294-1294 (2020-10-06)
Nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) inhibitors have potential as novel drugs for the (immuno)therapy of cancer. They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5'-nucleotidase (CD73) to immunosuppressive
T D Westfall et al.
European journal of pharmacology, 329(2-3), 169-173 (1997-06-25)
The influence of enzymatic degradation on the neurotransmitter actions of ATP was studied using the ecto-ATPase inhibitor 6-N,N-diethyl-D-beta,gamma-dibromomethyleneATP (ARL 67156). Field stimulation of the parasympathetic nerves innervating guinea-pig urinary bladder muscle strips (1-8 Hz for 20 s) produced characteristic biphasic
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service